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ABSTRACT
Objective: To assess the burden of diseases and
quality of life (QOL) of patients for a large variety of
diseases within general practice.
Design: In a representative nationwide cross-sectional
study, a total of 825 general practitioners (GPs) were
randomly selected from across France. Independent
investigators recruited 8559 patients attending the
GPs’ practices. Data on QOL (12-Item Short Form
questionnaire) and other individual characteristics
were documented by the independent investigators for
all participants in the waiting room. Medical
information was recorded by GPs. Sampling was
calibrated to national standards using the CALMAR
(CALage sur MARges) weighting procedure.
Associations of lower scores (ie, below vs above the
ﬁrst quartile) of physical and mental component
scores (physical component summary score (PCS)
and mental component summary score (MCS),
respectively) with main diseases and patients
characteristics were estimated using multivariate
logistic regression. Weighted morbidity rates, PCS and
MCS were computed for 100 diagnoses using the
International Classiﬁcation of Diseases (9th version).
Results: Overall mental impairment was observed
among patients in primary care with an average MCS
of 41.5 (SD 8.6), ranging from 33.0 for depressive
disorders to 45.3 for patients exhibiting fractures or
sprains. Musculoskeletal diseases were found to have
the most pronounced effect on impaired physical
health (OR¼2.31; 95% CI 2.08 to 2.57) with the lowest
PCS (45.6 (SD 8.8)) and ranked ﬁrst (29.0%) among
main diagnoses experienced by patients followed by
cardiovascular diseases (26.7%) and psychological
disorders (22.0%). When combining both prevalence
and QOL, musculoskeletal diseases represented the
heaviest burden in general practice.
Conclusions: Etude e ´pide ´miologique de l’Impact de
sante ´ public sur 3 groupes de pathologies (EPI3) is the
ﬁrst study to provide reference ﬁgures for burden of
disease in general practice across a wide range of
morbidities, particularly valuable for health-economics
and healthcare-system evaluation.
INTRODUCTION
Assessing and measuring the burden of
a disease in medical practice is undoubtedly
important for the evaluation of medicines
and healthcare.
1To assess such burden
quantitatively, both the prevalence of diseases
and their impact on health status and on the
quality of life (QOL) of patients need to be
taken into account.
2
In primary care, the prevalence of
morbidities has been shown to be remarkably
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ARTICLE SUMMARY
Article focus
- The impact of diseases on quality of life (QOL) in
general practice has been assessed among
selected samples of patients, usually from
studies including a limited number of medical
practices and/or focusing mainly on chronic
conditions.
- There is a clear need for more data on QOL of
patients in primary care; the aim of the Etude
e ´pide ´miologique de l’Impact de sante ´ public sur
3 groupes de pathologies (EPI3) survey was to
provide reference ﬁgures for disease burden in
this setting.
Key messages
- The EPI3 study was a cross-sectional survey
combining unique data from patients and general
practitioners (GPs), and allowed provision of
reference ﬁgures for the vast majority of diseases
encountered in primary care for a large number
of patients.
- The study highlighted the burden of musculo-
skeletal and psychological disorders, experi-
enced by more than half the patients.
- Although social and medical determinants of
patients’ QOL were somewhat similar than those
found in previous studies in primary care, the
EPI3 survey showed more pronounced mental
impairment in French patients.
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3e5
However, their effect upon QOL is only partially known.
6
The impact of the diseases on QOL in general practice
has been addressed so far using selected samples of
patients,
7e13 usually from studies including a limited
number of medical practices,
81 01 11 3and/or mainly
focused on chronic conditions.
79 e11 To the best of our
knowledge, no nationwide study of the burden of disease
combining both prevalence measures and QOL assess-
ment for a large variety of diseases is currently available.
To compensate for this paucity of information, some
studies have evaluated the impact for diseases in primary
care calling upon modelling data derived from studies in
medical specialties
14e16 and/or in hospital settings,
17 18
or from general population surveys.
19e21 It is not known
to what extent these extrapolations are appropriate.
The aim of the Etude e ´pide ´miologique de l’Impact de
sante ´ public sur 3 groupes de pathologies (EPI3) survey
was to provide reference ﬁgures for disease burden in
primary care. For this purpose, a representative sample
of general practitioners (GPs) was assembled through
stratiﬁed sampling and data from their patients collated
during a 1-day survey conducted by independent inter-
viewers in the waiting room of the participating medical
practices.
METHODS
Study design, settings and population
The EPI3 survey was a nationwide, observational study of
a representative sample of GPs and their patients,
conducted in France between March 2007 and July 2008.
Its aims were to assess the burden of diseases in general
practice, considering the physicians’ work activity,
patients’ characteristics, morbidity and prescriptions.
The sample was drawn by applying a two-stage
sampling process. First, GPs were randomly selected
from the French national directory of physicians and
invited to participate, which meant also allowing
a trained research assistant to conduct a 1-day survey in
the waiting room at the doctor’s practice. GPs’ sampling
was stratiﬁed according to the diversity of medicine
practices in the country (conventional and comple-
mentary medicine such as homeopathy).
The second stage consisted of random 1-day sampling
of consultations per participating physician in order to
survey all patients attending the practice on a particular
day. All adult and accompanied minor patients were
eligible for inclusion in the EPI3 survey to the exception
of those whose health status or literacy level did not
allow responding to a self-administered questionnaire.
The research assistant recruited up to a maximum of 15
patients on site (ie, in the waiting room) all eligible
patients listed consecutively who consented to partici-
pate in the survey. Further, each physician recorded
the main reason for consultation, along with the age,
gender and type of national health insurance for each
patient. The maximum number of patients surveyed
per day was set to allow sufﬁcient time for optimal
interviews and was followed by patients’ examination by
the physician.
The EPI3 survey obtained regulatory approval by the
national board of physicians (‘Conseil National de
l’Ordre des Me ´decins’) and ethical approval by the
French data protection authority (‘Commission Natio-
nale de l’Informatique et des Liberte ´s’). Patients were
informed by the participating physician that their
responses would be kept conﬁdential, and they were not
remunerated for participation. Physicians received
compensation fees. The study was sponsored by a phar-
maceutical company, whose name was not revealed to
investigators or patients.
Data collection
Patients were asked to self-complete a questionnaire
covering demographic and social information (age,
gender, educational level, employment status and occu-
pation, smoking, alcohol intake, physical activity, height
and weight for body mass index calculation), health
insurance (regular national insurance, welfare health
insurance for low income, with or without supplemen-
tary private insurance), number of visits to the partici-
pating physician within the last 12 months, or, for the
same period, to other GPs or medical specialists, the
length and number of hospitalisations and sick leaves.
Participants were asked whether the attending physi-
cian was their regular/primary care physician. In the
French health insurance system, patients have to choose
a regular physician, usually a GP, who plays a gate-
keeping role for referral to specialised care. However,
referral by regular GPs to other physicians is not
compulsory, and patients are allowed to seek care from
different physicians and their different reimbursement
schemes.
Detailed information on physicians including age,
gender, type of contract with national health insurance
(regular fees, additional fees and no contract), working
days and average duration of consultation were assessed
by the research assistants at the time of inclusion.
ARTICLE SUMMARY
Strengths and limitations of this study
- No nationwide study on burden of disease combining both
prevalence measures and QOL assessment has been
conducted to date, addressing such a large variety of diseases
in general practice.
- On-site selection and recruitment by an independent investi-
gator limited the possibility of selection bias among patients,
and the participation of physicians added high speciﬁcity to
medical data collection.
- A study design providing a high speciﬁcity in data collection led
to a relatively low response rate from GPs. However, stratiﬁed
recruitment phases and sample sizes from both GPs and
patients highly representative of national standards ensured the
strong external validity of the results.
- Home consultations, which are common among GPs in France,
were not surveyed which could have led to an underestimation
of the burden of disease.
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including the main reason for consultation and up to
ﬁve other diagnoses present that day. GPs were
requested to record their prescriptions that day for
diagnostic tests, drugs and referrals. Diagnoses were
coded by a trained archivist using the ninth revision of
the International Classiﬁcation of Diseases using 100-3
digit-categories.
22
Health-status measurement
Among adult patients (18 years and over), health-
related quality of life was assessed using the 12-Item
Short Form questionnaire (SF-12),
23 as h o r t e n e d
version of the 36-Item Short Form Health Survey (SF-
36) which has been shown to be a reliable outcome
measurement tool in primary care.
24 The physical and
mental component summary scores (PCS and MCS,
respectively) were derived from the SF-12 questionnaire.
Physical functioning (two questions), roledphysical
functioning (two questions), bodily pain (one ques-
tion), general health (one question), vitality (one
question), social functioning (one question), role-
demotional functioning (two questions) and mental
health (two questions) cover the same dimensions as
the SF-36. The scores are standardised to population
norms (based on a US norm-sample), with the mean
score set at 50 (SD 10); lower scores indicate worse
health, and higher scores better health. The SF-12 has
been validated for use in France, the USA, the UK and
many other European countries.
21
Statistical analysis
Participating and non-participating patients were
compared against the collected variables on gender, age,
length of time attending the GPs’ practice, type of health
insurance and main reason for consultation. A weighting
procedure known in demographic studies as the
CALMAR (CALage sur MARges) procedure was applied
to calibrate the ﬁnal sample according to participation
so that it closely represents the patients attending the
practice.
25
Participating GPs were compared with the French
‘Institut de recherche et documentation en e ´conomie de
la sante ´’ sample.
26The physicians’ activity-related frac-
tions were also calibrated to the real distribution of the
participating physicians across the France. All reported
results were obtained after weighting was applied to GPs’
patients.
In this study, we reported weighted prevalence, calcu-
lated as a percentage reported to the whole population,
regardless of whether the diagnosis was isolated or
associated with other diagnoses. Weighted PCS and MCS
measures of the SF-12 were computed according to the
algorithm given by Ware et al for 100 different condi-
tions, which were further grouped into 13 broad diseases
categories plus one covering preventive motives of
consultation and other medical acts.
23 Means and SDs
were estimated for the whole adult sample and for each
diagnosis. When a three-digit category from the ninth
revision of the International Classiﬁcation of Diseases
had <30 patients, the category was grouped with one or
several categories under the same heading. When
grouping within the same heading was not relevant,
categories with <30 patients were grouped in the
category ‘other’ within each main category.
Each disease category was calculated as a percentage
reported to the whole population of participating
patients over the age of 18 years, regardless of whether
this diagnosis was isolated or associated with others, in
order to provide a complete picture of morbidity cared
for in general practice.
Among adults over 18 years, associations of age,
gender, education, type of insurance and 13 broad
disease categories with lower MCS and PCS scores
(deﬁned as below the ﬁrst quartile with scores of 34 and
39 for MCS and PCS, respectively) were evaluated using
multivariate logistic regression. Odds ratios (OR) and
95% CI are presented for each of these factors. In
addition, the same analysis was conducted for the two
remaining categories, pregnancy follow-up and preven-
tive motives, which were not considered in the multi-
variate analysis. The association between the number of
comorbidities and the two SF-12 composite scores was
tested using linear regression. The possibility of a clus-
tering effect at the practice level was tested using
Generalised Estimating Equations multivariate models.
We used SAS statistical software (V.9.1) for data analysis.
The present study was reported following the
‘Strengthening the Reporting of Observational Studies
in Epidemiology’ statement for cross-sectional studies.
27
RESULTS
The sequential recruitment of physicians was carried out
by random stratiﬁed sampling from the phone directory
for GPs. Among the 3345 GPs initially contacted, 428
(12.8%) agreed to participate in the survey. At the end of
recruitment in July 2008, an additional sample of 13
861 GPs were contacted to ensure a representative
sample of GPs from all types of primary care practice in
France (strictly allopaths, homeopaths and mixed prac-
tice). Despite the intrusive nature of the survey, allowing
trained research assistants to collect data directly in
the waiting room at the medical practice on the very
day of consultation, a ﬁnal sample of 825 participating
GPs recruited a total of 11 809 patients eligible for the
present study. Of these, 174 were unaccompanied
minors, 315 were non-French speakers, 109 had severe
psychiatric disorders, 2151 declined participation, 408
were beyond the maximum number possible to be
interviewed within the allocated time on site, and 93 had
incomplete data and were excluded, allowing a total of
8559 patients for the present analysis.
Physicians
The median age of physicians was 52 years
(IQR¼33e57) and of these, 24% were women; 54%
worked in solo medical practice, 40% worked with other
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healthcare professionals; 31% of the GPs practised
additional medical activities within hospitals, healthcare
centres, the health administration or the pharmaceutical
industry. Most of the GPs (90%) hold a regular contract
with the National Health Insurance organisation, while
9% hold a special contract allowing extra fees; a very
small proportion (0.4%) had no contract. The mean
daily working time at the practice (excluding home
visits) was 9 h (IQR: 2e10.5), and each of the 825 GPs
participating in the study recruited on average 8.7
patients (SD 2.2).
Patients
The characteristics of participating (n¼8559) and non-
participating patients with complete data (n¼3157) used
to calibrate the sample are presented in table 1.W e
report here the results based on weighted characteristics.
The mean age of the 8559 participating patients was
44.9 years (SD 21.9), and 7133 (83.3%) were adults over
18. At least 44% of patients had a secondary-school
degree, 16% were overweight (BMI>30 kg/m
2), and
more than 61% exercised longer than 31 min per day.
Nine out of ten patients were French-born (90%), 9%
were covered by a government-funded insurance for low-
Table 1 Characteristics of non-participating and participating patients: results of the calibrated data (Etude e ´pide ´miologique
de l’Impact de sante ´ public sur 3 groupes de pathologies (EPI3) survey 2008)
Non-participants*
(n[3157)
Participants
(n[8559)
Weighted
percentage
Mean (SD)
Age (years) 47.7 (24.0) 43.3 (22.8) 44.9 (21.9)
n (%)
Female gender 1701 (53.9) 5367 (62.7) 57.9
Length of relationship with the physician
First time 265 (8.4) 782 (9.1) 7.7
<1 year 316 (10.0) 1315 (15.4) 11.9
1e5 years 743 (23.5) 2380 (27.8) 27.4
More than 5 years 1703 (53.9) 4015 (46.9) 53.0
Government-funded health insurance 308 (9.8) 621 (7.4) 9.4
Longstanding disease status 1925 (22.5) 27.7
Complementary health insurance 7839 (91.6) 90.3
Index physician declared as treating physician 6379 (74.5) 84.3
Body mass index (kg/m
2)
<25 5548 (64.8) 52.4
25e30 2045 (23.9) 31.8
30 and over 966 (11.3) 15.8
Tobacco consumption
Non-smoker 4303 (50.3) 47.4
Past smoker 1961 (22.9) 24.4
Current smoker 2252 (26.3) 28.2
Alcohol consumption
Never 2908 (34.2) 35.2
Sometimes 4649 (54.6) 52.5
Daily 957 (11.2) 12.4
Physical exercise
<10 min per day 2235 (26.1) 28.3
10 min and over 6199 (72.4) 71.7
Nationality
French-born subjects 7787 (91.0) 90.3
French born abroad 341 (4.0) 4.7
Non-French nationality 357 (4.2) 5.0
Educational attainment
Secondary-school degree*y,
college, university graduation
4179 (48.8) 44.0
Employment status
Employed 4544 (53.1) 50.4
On unemployment beneﬁts 378 (4.4) 4.7
Homemaker 647 (7.6) 6.6
Retired and other unemployed 2562 (29.9) 34.3
Student 348 (4.1) 4.1
*Available characteristics used for calibration.
yFrench baccalaureate.
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insurance. Among the 8559 patients, 8% had attended
the practice for the ﬁrst time, 12% had attended for
1 year or less, 27% had attended between 1 and 5 years,
and 53% had attended for 5 years or more. Over 84% of
participants named the recruiting physician as their
regular treating physician. About 28% of patients were
registered by the national health insurance as having
multiple or severe chronic diseases and requiring special
health insurance coverage.
Burden of 100 diseases in primary care
The prevalence of each of the 100 and 13 broad non-
exclusive diagnosis categories (a compilation of all ﬁve
diagnoses recorded by the GPs) is presented in table 2.
Altogether, diseases of the musculoskeletal system were
the most frequently diagnosed conditions (29%),
followed by cardiovascular diseases (26.7%), and sleep,
anxiety and depressive disorders (22%). Preventive-care
consultations, vaccinations and consultation for admin-
istrative purposes accounted for 19% of the total diag-
noses. Almost half the patients (49%) exhibited two or
more comorbidities.
Overall mean scores for PCS and MCS were 45.6 (SD
8.8) and 41.5 (SD 8.6), respectively. Considering PCS,
scores ranged from 40.3 (SD 11.0) for one group of
unspeciﬁed musculoskeletal conditions to 50.2 (SD 11.0)
for vaccinations. On the whole, musculoskeletal disor-
ders had the lowest scores with the cancer and other
severe diseases category, while skin-related diseases,
preventive-care consultation and infectious diseases
showed the highest PCS. With regard to MCS, scores
ranged from 33.0 (SD 10.2) for depressive disorders to
45.3 for patients with fractures, sprains or dislocation.
Overall, the lowest scores were found among patients
with mood and sleep disorders, while injury, preventive
motives and cardiovascular diseases exhibited the
highest scores. Both MCS and PCS decreased sig-
niﬁcantly with increasing numbers of comorbidities
(ﬁgure 1). For example, MCS decreased from 43.3 for
patients seeking preventive care advice to 38.5 for those
with four diagnoses or more (p for trend <0.0001) and
PCS from 49.2 to 40.4 (p for trend <0.0001).
Determinants of health-related quality of life
The associations between patient characteristics and 13
broad categories of diseases are presented in table 3.A
low PCS was signiﬁcantly associated with an older age
(OR¼2.48; 95% CI 2.08 to 2.96 for patients over 75 years
as compared with adults between 18 and 44 years). A low
PCS was negatively associated with a high educational
attainment (OR¼0.65; 95% CI 0.59 to 0.72 for secondary-
school level or higher in comparison with lower educa-
tional level), while low MCS scores were associated with
gender (OR¼1.62; 95% CI 1.45 to 1.81 for women as
compared with men) and younger age. Government-
funded health-insurance cover was associated with both
poor PCS and MCS (OR¼1.38; 95% CI 1.15 to 1.65 and
OR¼1.42; 95% CI 1.19 to 1.70, respectively).
With regard to the disease categories, musculoskeletal
diseases (OR¼2.31; 95% CI 2.08 to 2.57), injury and
poisoning (OR¼1.88; 95% CI 1.52 to 2.33), other
diseases including cancer (OR¼1.73; 95% CI 1.38 to
2.16), diseases of the nervous system, head and neck
(OR¼1.24; 95% CI 1.02 to 1.51) and cardiovascular
diseases (OR¼1.22; 95% CI 1.08 to 1.38) were signiﬁcant
predictors of lower PCS score, whereas the opposite was
found for skin and subcutaneous tissue diseases
(OR¼0.68; 95% CI 0.51 to 0.90) or with obesity and
dyslipidaemia (OR¼0.79; 95% CI 0.67 to 0.94). Signiﬁ-
cantly poor MCS were observed in patients suffering
from anxiety, depression and sleep disorders (OR¼3.58;
95% CI 3.22 to 3.98), and experiencing ‘other diseases’
including cancer (OR¼1.35; 95% CI 1.06 to 1.72).
Conversely, OR for MCS was signiﬁcantly decreased for
patients with cardiovascular diseases (OR¼0.84; 95% CI
0.73 to 0.96). Testing the effect of clustering at the
practice level yielded similar results, but to ensure
parsimony of the generated models it was decided not to
report such effects.
DISCUSSION
The EPI3 survey is, to our knowledge, the ﬁrst
nationwide survey in general practice to provide 100
reference ﬁgures for burden of disease assessment,
combining both on-site independent recruitment of
a large number of patients and additional medical
information from GPs. On-site selection and recruitment
by an independent investigator limited the possibility of
selection bias among patients, and the participation of
physicians added high speciﬁcity to medical data
collection.
There is a clear need for more data on QOL of
patients.
6 In the UK, the General Practice Research
Database assembled a very large sample of 400 surgeries
and 2500 individual GPs, providing detailed information
on health conditions besides prescriptions, but to our
knowledge not on patients’ QOL.
3 The Dutch national
survey of general practice carried out in 1987 and 2001
gives an assessment of quality of care, but only provided
by the patients themselves.
2
The EPI3 survey found a similar prevalence for both
diseases
10 28 and comorbidities
791 01 3as in several other
studies, which indicate a good representativeness of our
weighted sample. Musculoskeletal and psychological
disorders were experienced by more than half the
patients attending physicians during the course of the
study and represented a signiﬁcant case load at GP
practices. When both physical- and mental status impair-
ment and prevalence are considered, our study further
highlighted the heaviest burden of musculoskeletal
disorders.
With regard to physical status, the EPI3 survey showed
a similar average PCS score to other primary-care
7 81 01 1
or disease-speciﬁc
14 15 29 surveys using the SF-12 or SF-36
questionnaires. The mean PCS were lower than reference
values computed in the French reference sample
21 and in
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Benchmarking the burden of 100 diseasesTable 2 Morbidity rates and 12-Item Short Form questionnaire mental and physical component scores according to 100
International Classiﬁcation of Diseases diagnoses (Etude e ´pide ´miologique de l’Impact de sante ´ public sur 3 groupes de
pathologies (EPI3)-LA-SER-2008, weighted data n¼7133)
Diseases
Morbidity* PCS MCS
n (%) Mean (SD) Mean (SD)
All patients 45.6 (8.8) 41.5 (8.6)
Diseases of the musculoskeletal system 2069 (29.0) 42.7 (8.4) 41.6 (8.3)
Osteoarthritis 324 (4.5) 41.1 (10.7) 41.7 (11.0)
Unspeciﬁed joint disorders 171 (2.4) 42.5 (9.9) 42.6 (10.2)
Intervertebral and cervical disc disorders 276 (3.9) 44.0 (11.4) 40.6 (10.3)
Lumbago 360 (5.0) 42.1 (10.1) 41.6 (9.4)
Rotator cuff syndrome of shoulder and allied disorders 98 (1.4) 42.5 (10.1) 42.0 (9.8)
Other affections of shoulder region 121 (1.7) 42.6 (9.7) 42.4 (9.1)
Enthesopathy of elbow region 77 (1.1) 41.8 (9.3) 43.1 (10.5)
Unspeciﬁed enthesopathy 257 (3.6) 42.3 (10.5) 42.1 (10.0)
Rheumatism, excluding the back 112 (1.6) 42.9 (10.1) 42.3 (9.8)
Spondylosis and other inﬂammatory spondylopathies 84 (1.2) 42.1 (9.9) 43.1 (8.4)
Sciatica 194 (2.7) 42.3 (10.1) 41.7 (9.6)
Pain in thoracic spine 51 (0.7) 42.6 (9.8) 41.3 (9.2)
Osteoporosis 162 (2.3) 44.0 (10.7) 41.9 (10.8)
Diseases of connective tissue 36 (0.5) 45.5 (9.3) 40.5 (10.9)
Unspeciﬁed back disorders 193 (2.7) 42.1 (10.2) 41.3 (9.7)
Other unspeciﬁed musculoskeletal disorders 76 (1.1) 40.3 (11.0) 41.7 (11.6)
Hypertension, cardiovascular and circulatory diseases 1904 (26.7) 43.7 (9.0) 42.5 (8.6)
Hypertension 1111 (15.6) 43.9 (11.3) 42.8 (10.7)
Acute myocardial infarction 84 (1.2) 40.8 (11.4) 42.0 (9.4)
Other symptoms involving cardiovascular system 53 (0.7) 46.0 (9.5) 43.7 (8.2)
Angina pectoris 66 (0.9) 41.8 (11.8) 43.7 (10.5)
Cardiac dysrhythmias 139 (1.9) 42.9 (11.5) 42.7 (11.1)
Diseases of veins and lymphatics 92 (1.3) 45.3 (10.5) 41.3 (10.8)
Pulmonary, artery and cerebrovascular diseases 144 (2.0) 42.1 (11.7) 42.7 (10.6)
Other ischaemic heart diseases 96 (1.3) 41.1 (11.9) 42.1 (11.1)
Other diseases of the circulatory system 229 (3.2) 45.3 (10.3) 41.8 (11.0)
Anxiety, depression and sleep disorders 1569 (22.0) 44.8 (8.9) 36.3 (8.5)
Psychotic conditions 68 (1.0) 44.2 (12.6) 37.6 (12.3)
Anxiety states 420 (5.9) 47.8 (10.5) 35.5 (9.7)
Dysrhythmia 182 (2.6) 47.2 (10.2) 35.4 (9.2)
Acute and chronic stress 85 (1.2) 46.9 (10.6) 36.1 (9.5)
Personality disorders, disturbance of conduct and dependence
syndrome
81 (1.1) 46.4 (10.9) 38.8 (11.2)
Eating disorders, tics, stuttering and other syndromes 277 (3.9) 47.4 (10.4) 37.1 (10.7)
Depressive disorders 497 (7.0) 45.3 (11.4) 33.0 (10.2)
Malaise and fatigue 114 (1.6) 45.4 (11.1) 38.7 (9.7)
Sleep disorders 87 (1.2) 46.1 (10.7) 38.5 (9.4)
Nervousness, cachexia and unspeciﬁed psychological distress 30 (0.4) 41.9 (13.5) 39.9 (12.8)
Dizziness and giddiness 59 (0.8) 46.3 (9.8) 40.2 (10.4)
Other general symptoms 75 (5.8) 46.0 (11.1) 39.2 (10.4)
Diseases of the respiratory system 1419 (19.9) 46.3 (8.5) 41.9 (8.4)
Acute nasopharyngitis 306 (4.3) 48.2 (9.8) 41.6 (9.7)
Acute pharyngitis 60 (0.8) 49.3 (10.4) 42.5 (10.5)
Acute tracheitis 120 (1.7) 48.4 (10.1) 41.4 (10.4)
Acute bronchitis or other upper-respiratory infections 66 (0.2) 41.9 (12.3) 43.0 (8.0)
Chronic nasopharyngitis 52 (0.3) 50.0 (8.1) 42.9 (8.7)
Chronic sinusitis and laryngitis 126 (1.7) 48.0 (9.9) 40.3 (8.9)
Allergic rhinitis 124 (1.7) 47.5 (10.7) 42.3 (9.6)
Pneumonia and ﬂu 53 (0.6) 46.8 (10.2) 41.1 (10.8)
Chronic obstructive pulmonary diseases (except asthma) 160 (2.2) 44.8 (10.4) 41.2 (10.0)
Asthma 148 (2.1) 44.0 (11.5) 41.4 (10.5)
Lung diseases 64 (0.9) 41.0 (12.3) 42.0 (9.5)
Other diseases of the respiratory system 210 (2.9) 45.1 (11.6) 42.4 (10.4)
Medical exams and preventive motives 1101 (15.4) 47.4 (9.2) 42.4 (10.1)
Continued
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Diseases
Morbidity* PCS MCS
n (%) Mean (SD) Mean (SD)
Medical exam: handicap inﬂuencing health status 41 (0.6) 45.9 (9.4) 39.4 (12.6)
Medical exam: aftercare and speciﬁc procedures 285 (4.0) 45.9 (11.6) 41.2 (10.8)
Medical exam for health check-up 286 (4.0) 46.9 (11.3) 43.1 (10.8)
Laboratories ﬁndings 53 (0.7) 48.5 (9.8) 42.9 (10.9)
Vaccination 121 (1.7) 50.2 (11.0) 42.6 (10.5)
Pregnancy follow-up 122 (1.7) 47.4 (11.8) 41.8 (10.4)
Administrative purposes 380 (5.3) 47.2 (11.7) 42.5 (9.9)
Diabetes, thyroid gland and other endocrine disorders 785 (11.0) 43.9 (8.6) 41.5 (8.1)
Hypothyroidism 187 (2.6) 45.3 (11.0) 39.6 (10.9)
Goitre 45 (0.6) 46.5 (9.3) 41.3 (9.8)
Diabetes mellitus 312 (4.4) 42.9 (11.2) 42.0 (10.5)
Diseases of other endocrine glands 78 (1.1) 43.9 (11.9) 41.0 (10.8)
Other thyroid disorders 52 (0.7) 45.7 (10.8) 40.0 (10.1)
Obesity and dyslipidaemia 742 (10.4) 45.2 (9.1) 42.0 (8.9)
Hypercholesterolaemia 266 (3.7) 45.1 (10.9) 42.6 (10.2)
Unspeciﬁed disorder of lipoid metabolism 135 (1.9) 45.5 (10.5) 42.8 (9.2)
Overweight, obesity and other hyperalimentation 169 (2.4) 47.6 (11.4) 40.2 (10.4)
Other hyperlipidaemia 105 (1.1) 45.6 (11.3) 42.4 (10.6)
Other symptoms concerning nutrition, metabolism and
development
70 (1.0) 48.6 (10.1) 40.3 (10.4)
Diseases of the digestive system 742 (10.4) 45.9 (8.4) 39.9 (8.4)
Oesophageal diseases 81 (1.1) 44.3 (10.3) 41.5 (9.8)
Diseases of stomach 121 (1.7) 45.6 (10.0) 40.1 (9.7)
Diseases of intestines and peritoneum 72 (1.0) 45.1 (10.1) 40.2 (9.9)
Symptoms involving the abdomen 161 (2.3) 46.9 (10.4) 39.9 (11.0)
Non-infectious enteritis and colitis 105 (1.5) 47.5 (9.5) 41.8 (9.9)
Diseases of oral cavity, salivary glands and jaws 39 (0.5) 49.0 (8.8) 40.3 (10.0)
Appendicitis and hernia 43 (0.6) 44.1 (10.6) 40.0 (10.2)
Other diseases of the digestive system 144 (2.0) 44.8 (10.8) 39.7 (9.9)
Diseases of the nervous system, head and neck 449 (6.3) 43.3 (9.4) 39.6 (9.1)
Disorders of the central nervous system 95 (1.3) 41.3 (13.6) 42.2 (11.2)
Migraine 114 (1.6) 46.6 (10.2) 39.7 (10.1)
Symptoms involving the head and neck 96 (1.3) 46.3 (10.8) 40.8 (10.2)
Diseases of the eye 54 (0.7) 51.8 (9.9) 37.4 (10.6)
Diseases of the ear and mastoid processes 112 (1.6) 46.9 (10.8) 41.6 (11.0)
Other disorders of the nervous system and sense organs 145 (2.0) 44.6 (10.3) 39.9 (10.6)
Diseases of the genitourinary system 400 (5.6) 45.5 (9.6) 41.5 (8.9)
Cystitis 115 (1.6) 47.9 (11.5) 40.3 (10.2)
Diseases of male genital organs 85 (1.2) 46.0 (10.9) 43.0 (11.0)
Diseases of female genital organs 139 (1.9) 48.4 (11.3) 39.8 (10.8)
Nephrosis and nephritis 86 (1.2) 44.8 (11.6) 41.7 (10.6)
Complications of pregnancy and congenital anomalies 42 (0.6) 43.5 (12.8) 40.4 (10.5)
Injury and poisoning 342 (4.8) 43.5 (9.2) 43.5 (8.3)
Fractures, sprains and dislocations 103 (1.4) 41.9 (10.5) 45.3 (9.7)
Traumas and injuries to organs 54 (0.8) 44.3 (12.9) 44.1 (11.4)
Burns and amputations 62 (0.9) 44.4 (11.6) 43.1 (10.4)
Intoxications and allergies to toxic drugs 108 (1.5) 47.3 (11.6) 41.5 (10.7)
Poisoning, other allergy and side effect of surgery 55 (0.8) 44.3 (11.1) 40.3 (9.3)
Cancer and infrequent diseases 289 (4.1) 42.0 (9.3) 40.4 (8.5)
Neoplasms 174 (2.4) 41.8 (11.6) 40.7 (10.6)
Benign tumours 54 (0.8) 44.7 (10.9) 40.8 (10.7)
Blood diseases 56 (0.8) 45.3 (11.1) 41.2 (9.5)
Skin and subcutaneous tissue diseases 243 (3.4) 48.8 (7.8) 41.7 (9.6)
Infections of skin and subcutaneous tissue 55 (0.8) 46.1 (11.0) 40.4 (11.3)
Inﬂammatory conditions of skin and subcutaneous tissue 163 (2.3) 47.3 (9.9) 42.2 (10.4)
Other diseases of skin and subcutaneous tissue 89 (1.2) 49.7 (8.5) 40.1 (11.0)
Infectious diseases 228 (3.2) 47.1 (7.6) 40.7 (7.1)
Parasitic diseases 76 (1.1) 47.1 (11.1) 42.1 (10.7)
Continued
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Benchmarking the burden of 100 diseasesthe 2003 Household survey (JL Lanoe, unpublished data,
2003). Within practices, older age,
30e33 low education
attainment and government-funded insurance
30 32 33
were associated with lower PCS. When disease categories
were considered, musculoskeletal diseases were associ-
ated with the lowest PCS,
83 43 5with PCS of similar
magnitude to other European surveys including muscu-
loskeletal diseases patients.
29
Regarding mental status, although socio-demographic
characteristics had a similar impact on MCS, the EPI3
survey showed signiﬁcantly lower MCS scores than other
studies in general practice.
7 81 01 1Additional comor-
bidities, which were reported for half of the EPI3 survey
sample, could not alone explain this difference with
other studies: MCS usually scored an average three
points lower than those of patients with one morbidity.
16
We believe that our ﬁndings could be explained instead
by a different methodology: in all other studies
conducted in general practice,
7 8 10 11 mostly including
a small number of medical practices,
81 01 11 3physicians
may have selected participants. Our study was free from
this bias in view of the selection of consecutive eligible
patients in the GP’s waiting room. In studies in which
patients were interviewed for targeted mental disorders
15
or when MCS were assessed among patients seeking
specialty care,
36 37 MCS measures were somewhat similar
to ours. In the EPI3 survey, psychological and psychiatric
diseases had the greatest negative impact on mental
function consistent with other surveys in primary
care
71 0 ; it must be appreciated that associated MCS
values were more similar to those of another study
conducted on patients with speciﬁc psychiatric disor-
ders.
15 Lower MCS may thus highlight the overall
burden of psychological distress and related diseases of
patients seen in primary care.
Strengths and limitations of the study
Among the main strengths of our study, the unique
combined data from patients and physicians allowed
provision of reference ﬁgures for the vast majority of
diseases encountered in primary care for a large number
of patients. Quality-adjusted life years are usually esti-
mated for health economics and mainly derived from
QOL measures assessed from EuroQoL standardised
instruments (EQ5D).
1Interestingly, the conversion of
SF-12 values into EQ5D Utility values has been recently
documented,
38 suggesting that our results could be
extended for that purpose as previously reported.
39
Aditionally, SF-12 questionnaires have been found to
provide reliable QOL measurement across studies,
22 24
even among patients with acute conditions.
40 Although
its validity in older patients is moderate,
41 our sample was
representative of the general population, thus minimising
this possible bias on our results.
Finally, a lack of representativeness was an important
limitation in other studies.
11 42 The sample size of
physicians participating in the EPI3 survey is within the
range established for other French surveys (from 100 to
1006).
26 Physicians were randomly selected from the
national telephone directory, which includes general
practitioners currently practising in primary care. This
was preferred to professional registries of physicians,
which lists all registered GPs, regardless of whether they
are currently practising or not.
The weighted geographical distribution of the 825 GPs
participating in the survey was similar to the national
distribution of GPs in private practice across the 22
French regions surveyed, and the distribution of physi-
cians’ individual characteristics regarding age, gender
type of contract with national health insurance and type
of practice differed only slightly from national statis-
tics
26: female participation was slightly lower (23.5%
compared with 26% in the IRDES sample), but the
distribution between sectors was similar (8.9% vs 8.5% in
sectors 1 and 2, respectively).
In terms of the representativeness of the patients, the
calibrated sample of the EPI3 survey was compared with
other nationwide studies and has demonstrated its efﬁ-
ciency through other criteria that were not used in the
Table 2 Continued
Diseases
Morbidity* PCS MCS
n (%) Mean (SD) Mean (SD)
Bacterial diseases 82 (1.1) 47.0 (10.0) 39.9 (9.8)
Viral diseases (including HIV) 122 (1.7) 46.5 (11.6) 40.5 (10.1)
Fever and other physiological disturbances of temperature regulation 77 (1.1) 46.3 (10.4) 40.1 (8.4)
*Each condition category is non-exclusive.
SF-12 MCS and PCS according to number of comorbidities
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Figure 1 Health-related quality of life: 12-Item Short Form
questionnaire (SF-12) mental (MCS) and physical (PCS)
component scores per number of comorbidities Etude
e ´pide ´miologique de l’Impact de sante ´ public sur 3 groupes de
pathologies (EPI3)-2008 (weighted data).
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28 For instance, patients registered by health
insurance as eligible to the ‘longstanding disease’
programme accounted for 28% in the EPI3 survey, which
is very similar to the 27% in national census among GP
patients.
28
Our study also had several limitations. First, as
outlined earlier, requirement to collect very speciﬁc data
was quite intrusive, leading to a relatively low response
rate from the GPs. However, stratiﬁed recruitment
phases and sample sizes from both GPs and patients
highly representative of national standards ensured
strong external validity of the results. Second, we did not
include an assessment of home consultations, common
among GPs in France,
27which could have led to an
underestimation of burden of disease. Finally, a multi-
plicative effect of morbidity which has been found to be
associated with QOL impairment was not assessed in our
study. Some authors suggested using severity scores to
complement the information on morbidity
12 13and
assess the impact of multimorbidity, which have already
been tackled here but will be the subject of further
development in future research within the EPI3 research
project. It was a deliberate choice to provide an instant
overview of general practice across France and the
burden of a large pattern of diseases on patients’ QOL as
shown in previous studies which also described an
independent effect of diseases on QOL.
9e11
CONCLUSION
The EPI3 survey is the ﬁrst nationwide study to report
reference values for the burden of 100 different diseases
in general practice, collected from a large representative
sample of patients attending primary care practices. Our
ﬁndings suggest that mental impairment may be
underestimated in general practice. Ongoing develop-
ment of healthcare policies and clinical guidelines on
the treatment of diseases should rely on a direct assess-
ment of QOL and morbidities in GP medical practices.
GPs foster continuous care, sometimes requiring
highly specialised therapy to deal with comorbidities and
complex situations. The present study shows that the
burden of diseases in primary care is high but also can be
diverse. The EPI3 survey provides information on the
overall burden of diseases in general practice along with
the QOL of patients regarding comorbidities as seen in
this healthcare setting. This information is of great value
to public health and economic assessment of healthcare,
at a time when QOL is becoming a prevalent factor for
care delivery and the development of clinical practice
guidelines.
Table 3 Health-related quality of life: 12-Item Short Form questionnaire, with Factors and 13 broad diagnoses associated with
mental component score and physical component score below the 25th percentile (OR from multivariable logistic regression
models adjusted for age, gender, education level, insurance coverage and 13 categories of diseases (aOR) and 95% CI), for
Etude e ´pide ´miologique de l’Impact de sante ´ public sur 3 groupes de pathologies (EPI3)-LA-SER-2008 (weighted data)
Low physical component
score
Low mental component
score
aOR* 95% CI aOR* 95% CI
Age (years)
18e4 4 11 11
45e64 1.22 1.08 to 1.39 0.96 0.85 to 1.08
65e74 1.47 1.25 to 1.73 0.65 0.55 to 0.78
75 and over 2.48 2.08 to 2.96 0.70 0.57 to 0.86
Gender: female versus male 1.03 0.93 to 1.14 1.62 1.45 to 1.81
Education: secondary school degree
versus lower diploma
0.65 0.59 to 0.72 1.00 0.90 to 1.11
Government-funded insurance (vs regular
health insurance)
1.38 1.15 to 1.65 1.42 1.19 to 1.70
Diseases of the musculoskeletal system 2.31 2.08 to 2.57 0.95 0.85 to 1.06
Cardiovascular diseases 1.22 1.08 to 1.38 0.84 0.73 to 0.96
Anxiety, depression and sleep disorders 0.99 0.88 to 1.11 3.58 3.22 to 3.98
Diseases of the respiratory system 1.03 0.91 to 1.18 0.91 0.80 to 1.04
Obesity and dyslipidaemia 0.79 0.67 to 0.94 0.93 0.78 to 1.11
Diabetes, thyroid gland and other endocrine
disorders
1.15 0.97 to 1.35 1.18 0.99 to 1.41
Diseases of the digestive system 1.01 0.86 to 1.19 1.15 0.89 to 1.38
Diseases of the genitourinary system 0.95 0.76 to 1.19 1.11 0.89 to 1.38
Diseases of the nervous system, head and
neck
1.24 1.02 to 1.51 1.07 0.88 to 1.31
Skin and subcutaneous tissue diseases 0.68 0.51 to 0.90 0.92 0.71 to 1.19
Bacterial, viral and parasitic systemic diseases 1.17 0.89 to 1.54 1.12 0.86 to 1.48
Injury and poisoning 1.88 1.52 to 2.33 0.80 0.61 to 1.03
Other diseases (cancer and infrequent diseases) 1.73 1.38 to 2.16 1.35 1.06 to 1.72
*aOR, adjusted odds ratio.
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